Cardio-Oncology Webinar Series
Thanks to incredible recent advances in therapeutic options for cancer treatment, survival from cancer is increasing worldwide. While this increase in cancer survivorship represents an outstanding achievement, there has been increasing recognition of the toxicities of cancer therapies, in particular cardiovascular diseases that affect morbidity, mortality, and quality of life of cancer patients. Cardiovascular disease is now the leading cause of morbidity and mortality among cancer survivors.
Cardio-oncology focusses on the management of cardiovascular health in cancer patients, an emerging field with immense potential to improve cancer survivors’ quality of life. Cardio-oncology has rapidly grown to a more mature and well-established subspecialty in the last decade. Our knowledge of mechanisms and clinical manifestations of cardiotoxicity has been expanding at a rapid pace.
Throughout these webinars we will hear from experts on latest developments in this new and rapidly emerging field. The second part of our webinar series will focus on the immune checkpoint inhibitor-associated myocarditis as well as nexus between heart failure and cancer.
Part 2 Featured Speakers
Start Date 13 July 2022 | Start Time 3:00 PM AEST | Duration 75 min
Presentation Topic
Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: From Mice to Men
Prof Javid Moslehi
MD
William Grossman Distinguished Professor in Cardiology
Section Chief, Cardio-Oncology & Immunology
Associate Professor in Residence
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
Presentation Topic
Heart Failure and Cancer: Dangerous Liaisons
A/Prof Carlo Gabriele Tocchetti
MD PhD FHFA FISC
Associate Professor of Medicine
Director, Cardio-Oncology Unit
Department of Translational Medical Sciences
Center for Basic and Clinical Immunology Research (CISI)
Interdepartmental Center for Clinical and Translational Research (CIRCET)
Interdepartmental Hypertension Research Center (CIRIAPA)
University of Naples Federico II
Hosted by the Directors of the Newcastle Centre of Excellence in Cardio-Oncology:
A/Prof Aaron Sverdlov
MBBS PhD FRACP FCSANZ FESC FHFA FACC
Director of Heart Failure, University of Newcastle, Australia
Co-Director, Newcastle Centre of Excellence in Cardio-Oncology
National Heart Foundation Future Leader Fellow
A/Prof Doan Ngo
B.Pharm PhD FCSANZ FESC
Co-Director, Newcastle Centre of Excellence in Cardio-Oncology
National Heart Foundation Future Leader Fellow
A/Prof Aaron Sverdlov
MBBS PhD FRACP FCSANZ FESC FHFA FACC
Director of Heart Failure, University of Newcastle, Australia
Co-Director, Newcastle Centre of Excellence in Cardio-Oncology
National Heart Foundation Future Leader Fellow
A/Prof Sverdlov is a Clinical Academic Cardiologist internationally recognised for his expertise in cardiovascular research from fundamental discovery through to translation and clinical application.
He is co-director of the Cardio-Oncology Program based at the Calvary Mater Newcastle Hospital (a collaboration between Calvary Mater Newcastle, HMRI, Hunter New England Local Health District, and the University of Newcastle) which has been designated a Center of Excellence by the International Cardio-Oncology Society – receiving the highest tier accreditation of GOLD status and is the only centre in Australia to have been awarded this certification.
A/Prof Sverdlov was also the founding member of the first National Cardio-Oncology Special Interest Group under the auspices of Australian Cardiovascular Alliance, is co-director of the Cardiometabolic Research Group in Newcastle and is a member of numerous cardiology and oncology groups and committees.
In 2021 he was awarded a four-year Future Leader Fellowship from the National Heart Foundation of Australia to investigate strategies to improve the heart health for people living with and beyond cancer.
A/Prof Doan Ngo
B.Pharm PhD FCSANZ FESC
Co-Director, Newcastle Centre of Excellence in Cardio-Oncology
National Heart Foundation Future Leader Fellow
A/Prof Ngo is an expert in cardiometabolic pathophysiology with a focus on obesity, redox stress and vascular biology. She has made key contributions in the field of adipose tissue biology and angiogenesis and its effects on the cardiovascular system.
A/Prof Ngo is co-director of the Cardio-Oncology Program based at the Calvary Mater Newcastle Hospital (a collaboration between Calvary Mater Newcastle, HMRI, Hunter New England Local Health District, and the University of Newcastle) which has been designated a Center of Excellence by the International Cardio-Oncology Society – receiving the highest tier accreditation of GOLD status and is the only centre in Australia to have been awarded this certification.
In 2020 she was awarded a four-year Future Leader Fellowship from the National Heart Foundation of Australia to investigate strategies to prevent and reduce the cardiovascular burden in cancer survivors, co-director of the Cardio-metabolic Research Group, co-chair of the AcVA Cardio-Oncology working group and writing group and is a member of numerous cardiology and oncology groups and committees.
Prof Javid Moslehi, MD
William Grossman Distinguished Professor in Cardiology
Section Chief, Cardio-Oncology & Immunology
Associate Professor in Residence
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
Prof Moslehi is a cardiologist and myocyte biologist specialising in the cardiovascular health of cancer patients, cancer survivors and patients with immunological or metabolic problems that affect cardiovascular health.
He currently serves as chief of the UCSF cardio-oncology and immunology section, with his research focus on investigating the mechanistic underpinnings of cardiovascular sequelae of novel targeted and immune-based cancer therapies.
Prof Moslehi earned his medical degree from the University of Connecticut School of Medicine. He completed his residency in internal medicine at the Johns Hopkins Hospital followed by a fellowship in cardiology and postdoctoral research fellowship in oncology, at the Brigham and Women’s Hospital.
His career includes directing cardio-oncology programs at the Dana-Farber Cancer Institute and Vanderbilt University Medical Center. In 2021 he was awarded the inaugural UCSF William Grossman Distinguished Professorship in Cardiology.
A/Prof Carlo Gabriele Tocchetti
MD PhD FHFA FISC
Associate Professor of Medicine
Director, Cardio-Oncology Unit
Department of Translational Medical Sciences
Center for Basic and Clinical Immunology Research (CISI) Interdepartmental Center for Clinical and Translational Research (CIRCET) Interdepartmental Hypertension Research Center (CIRIAPA)
University of Naples Federico II
A/Prof Tocchetti is currently the Associate Professor of Medicine and Director of the Cardio-Oncology Unit in the Department of Translational Medical Sciences at the University of Naples Federico II. He coordinates the Heart Failure outpatient unit mostly dedicated to post ischemic heart failure, right ventricular (RV) dysfunction and pulmonary hypertension, and the follow-up of oncologic patients before, during and after undergoing antineoplastic protocols.
A/Prof Tocchetti received his medical degree, his Board in Cardiology, and PhD from the University of Naples Federico II. He is a Fellow of the Heart Failure Association (HFA), 2020-2022 Chair of the Study Group on Cardio-Oncology of the HFA, of the HFA Translational Research Committee, and of the Working Group on Myocardial Function of the European Society of Cardiology (ESC). He is also a current Board Member of the ESC Council on Basic Cardiovascular Science, and Council of Cardio- Oncology.
A/Prof Tocchetti has established himself as a heart failure basic and clinical investigator, with his lab focussing on exploring the pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic heart failure, genetic and inflammatory cardiomyopathies, pulmonary hypertension and RV dysfunction, and heart failure due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.
